【北科生物是哪个国家的品牌？】

外推网助力北科生物品牌出海！通过在本页面挂载北科生物品牌的产品链接和联系邮箱，可以提高北科生物产品曝光！跨境电商爆单神器，目前只要100元/年哦~

深圳市北科生物科技有限公司（以下简称：北科生物）创建于2005年7月，是我国较早专业从事战略性新兴产业生物治疗技术临床转化及技术服务的高新技术企业。公司拥有员工400多名，其中35%以上为技术研发人员，拥有在细胞领域成果卓越的多位专家及国内外学者领衔的专业技术研发团队。

多个子公司：江苏北科、上海北科、安徽北科、辽宁北科、河南北科、贵州北科、江西北科、河北北科、北科国际（香港）、北科国际（印度）等。

全球临床研究技术支持网络：北科生物与国内外400多家科研及医疗机构开展了细胞技术相关合作，已为80000多人次难治性疾病患者的细胞治疗提供个体化细胞制备技术服务，包括来自美国、加拿大、英国、日本等70多个国家的患者，显著效果得到国际学术界的高度认可。

先进的免疫细胞治疗技术：通过战略性授权，并购和自主研发，北科在免疫治疗领域占有重要的战略地位。北科拥有多种国际先进的免疫治疗技术和产品。ALT803被NCI认为是比较有希望治愈癌症的白介素类药物。在主要组织相容性复合物抗原识别受体研发平台开发下的抗体，双特异性抗体、MCAR-T、MCAR-NK细胞治疗比目前的常规的CAR-T、TCR-T和双特异性抗体，在恶性血液病、实体瘤和病毒感染等疾病面具有更显著的治疗优势。

综合细胞库暨区域细胞制备中心国家网络：通过“铺设”一条既能满足临床需求及时性、又兼顾生产规模化的联通临床需求方和先进技术供给方的“细胞治疗高速公路网”，为细胞治疗技术临床转化提供了创新性的公共技术平台和基础设施；已先后在深圳、江苏、贵州、江西、广西、新疆建成并取得令人瞩目的成绩，为我国细胞治疗产业发展模式提供一条可借鉴的创新之路。

英文翻译：Founded in July 2005, Shenzhen Beike Biotechnology Co., Ltd. (hereinafter referred to as Beike Biotechnology) is an early high-tech enterprise specialized in clinical transformation and technical services of biological treatment technology in strategic emerging industries in China. The company has more than 400 employees, more than 35% of whom are technical R & D personnel. It has a number of experts with outstanding achievements in cell field and a professional R & D team led by domestic and foreign scholars. Many subsidiaries: Jiangsu Beike, Shanghai Beike, Anhui Beike, Liaoning Beike, Henan Beike, Guizhou Beike, Jiangxi Beike, Hebei Beike, Beike International (Hong Kong), Beike International (India), etc. Global clinical research technology support network: Beike biology has cooperated with more than 400 research and medical institutions at home and abroad in cell technology, and has provided individualized cell preparation technology services for cell therapy of more than 80000 patients with refractory diseases, including patients from more than 70 countries, including the United States, Canada, the United Kingdom, Japan, etc., with remarkable effects highly recognized by the international academic community Yes. Advanced immunotherapy Technology: through strategic authorization, M & A and independent research and development, Beike occupies an important strategic position in the field of immunotherapy. Beike has a variety of international advanced immunotherapy technologies and products. Alt803 is considered by NCI to be a promising interleukin drug to cure cancer. The antibody, bispecific antibody, mcar-t, mcar-nk cell therapy under the development of the main histocompatibility complex antigen recognition receptor platform has more significant therapeutic advantages than the current conventional car-t, tcr-t and bispecific antibody in the treatment of malignant hematopathy, solid tumor, virus infection and other diseases. National network of comprehensive cell bank and regional cell preparation center: through "laying" a "cell treatment expressway network" connecting clinical demand side and advanced technology supply side, which can meet clinical demand timeliness and take into account production scale, it has provided innovative public technology platform and infrastructure for clinical transformation of cell treatment technology; it has been successively in Shenzhen, Jiangsu, Jiangsu Guizhou, Jiangxi, Guangxi and Xinjiang have made remarkable achievements, which provides an innovative way for the development of cell therapy industry in China.

本文链接： https://www.waitui.com/brand/4357e0f5e.html 联系电话：请联系客服添加